

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

RESULTS ESTIMATE

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (“**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2024, it is expected that:

- 1) the Group will record a revenue of approximately RMB3,084 million to RMB3,144 million for the six months ended June 30, 2024, representing a decrease of approximately 7.0% to 8.8% as compared to RMB3,382 million for the corresponding period of last year. Such expected decrease in revenue is mainly attributable to (a) the decrease in revenue from promotion service, which includes: i) the termination of the promotion service agreement with Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (and its affiliates) due to the entry of the centralized procurement of Softan[®] (Rosuvastatin Calcium Tablets); and ii) the revenue from promotion service of ENWEIDA[®] (Envafolimab Injection) falling short of expectations; and (b) the decrease in the sales revenue of XIANNUOXIN[®] (Simnotrelvir Tablets/Ritonavir Tablets (co-packaged)) after the change of COVID-19 pandemic situation.

- 2) the Group will record a profit attributable to equity shareholders of the Company of approximately RMB427 million to RMB487 million for the six months ended June 30, 2024, representing a decrease of approximately 78.6% to 81.2% as compared to RMB2,274 million for the corresponding period of last year. Such expected change in profit attributable to equity shareholders of the Company is mainly attributable to: (a) the change in fair value of the shares of 3D Medicines Inc. held by the Group (measured based on the closing price of the shares of 3D Medicines Inc.) led to a net fair value loss before tax of approximately RMB48 million recorded in the six months ended June 30, 2024, while a net gain before tax of approximately RMB1,134 million recorded for such investment in the corresponding period of last year; and (b) one-off gain before tax of approximately RMB789 million recorded by the Group from the disposal of interest in subsidiaries in the corresponding period of last year. Without taking into account the impacts of the above investment projects and one-off profit or loss items, the Group's profit attributable to equity shareholders of the Company for the six months ended June 30, 2024 will record a relatively substantial growth as compared to the corresponding period of last year.

The Group prepared its consolidated financial information in respect of the acquisitions by applying the principles of merger accounting. Since the acquisition of Nanjing Jiayuantang Biological Technology Co., Ltd. (the “**Acquisition**”) was completed in November 2023, the comparative consolidated financial information of the Group for the six months ended June 30, 2023 has been restated as if the Acquisition had been completed at the beginning of the comparative period. The above restated financial information has not been audited or reviewed by the auditor. For more details on the Acquisition, please refer to the announcement of the Company dated January 1, 2024.

The Company is still in the process of finalising the interim results of the Group for the six months ended June 30, 2024. The information contained in this announcement is based solely on the preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended June 30, 2024, and is subject to finalisation and other potential adjustments, if any, and has not been reviewed or confirmed by the Group's auditors or the audit committee of the Board. Shareholders and potential investors of the Company should refer to the Group's interim results announcement for the six months ended June 30, 2024, which is expected to be published in late August 2024.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, July 30, 2024

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.